Xingxiang Xu

机构：Hanzhong People's Hospital

发表论文 61 篇 · 总被引 1311 次 · h-index 16

代表论文

• Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial (2021 · Journal of Thoracic Oncology · 被引 323)
• Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial (2021 · Journal of Thoracic Oncology · 被引 150)
• On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial (2022 · Molecular Cancer · 被引 54)
• A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection (2022 · CHEST Journal · 被引 49)
• 96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial (2021 · Journal of Thoracic Oncology · 被引 20)
• Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial (2023 · Signal Transduction and Targeted Therapy · 被引 18)